


Supplementary Table 1: Search Strategy


Search Strategy (Pubmed)	
#1	((vortioxetine[Title/Abstract] OR Lu AA21004[Title/Abstract]) OR Brintellix[Title/Abstract])
#2	((((anxiety[Title/Abstract] OR anxiety disorder[Title/Abstract]) OR anxiety disorders[Title/Abstract]) OR mood disorder[Title/Abstract]) OR mood disorders[Title/Abstract])
#3	Search "Anxiety Disorders"[Mesh]
#4 (#2 OR #3)	("Anxiety Disorders"[Mesh] OR (((((anxiety[Title/Abstract] OR anxiety disorder[Title/Abstract]) OR anxiety disorders[Title/Abstract]) OR mood disorder[Title/Abstract]) OR mood disorders[Title/Abstract]))
#5 (#1 OR #4)	((("Anxiety Disorders"[Mesh] OR (((((anxiety[Title/Abstract]/ OR anxiety disorder[Title/Abstract]) OR anxiety disorders[Title/Abstract]) OR mood disorder[Title/Abstract]) OR mood disorders[Title/Abstract]))) AND (((vortioxetine[Title/Abstract] OR Lu AA21004[Title/Abstract]) OR Brintellix[Title/Abstract]))
#6	Filters: Clinical Trial; Randomized Controlled Trial



Supplementary Figure 1: Search flow for the trial identification and selection process.


	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Bidzan 2012	?	?	+	+	+	?
Mahableshwarkar 2014a	?	?	+	+	+	?
Mahableshwarkar 2014b	+	+	+	+	+	?
Rothschild 2012	+	+	+	+	+	?

Supplementary Figure 2: Summarized risks of bias for the included studies.



Supplementary Figure 3: Odds ratios (ORs) and 95% confidence intervals (CIs) of the selected studies and the pooled data, comparing the discontinuation rates for any reason, between the vortioxetine and placebo groups.

Notes: (A) 2.5-mg/day vortioxetine versus placebo, (B) 5-mg/day vortioxetine versus placebo, and (C) 10-mg/day vortioxetine versus placebo.



Supplementary Figure 4: Odds ratios (ORs) and 95% confidence intervals (CIs) of the selected studies and the pooled data, comparing the discontinuation rates due to adverse events (AEs), between vortioxetine and placebo groups.

Notes: (A) 2.5-mg/day vortioxetine versus placebo, (B) 5-mg/day vortioxetine versus placebo, and (C) 10-mg/day vortioxetine versus placebo.